deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus pemetrexed plus platin
nivolumab plus ipilimumab vs. pemetrexed plus platin 1 1.0better0.35.099 %1.0better0.35.099 %-